Improvements in benign prostatic hyperplasia‐specific quality of life with dutasteride, the novel dual 5α‐reductase inhibitor
Authors:
Open Access
- 23 July 2003
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 92 (3) , 262-266
Abstract
OBJECTIVES: To examine the effect of the dual‐action 5α−reductase inhibitor dutasteride on benign prostatic hyperplasia (BPH)‐specific health status, as measured by the BPH Impact Index (BII), and to identify baseline and treatment risk factors for those most bothered by their BPH symptoms at the end of the protocol. PATIENTS AND METHODS: Data were derived from three randomized, double‐blind, placebo‐controlled, 2‐year studies conducted in 4325 men with lower urinary tract symptoms caused by benign prostatic enlargement. Each study comprised a 1‐month single‐blind placebo run‐in period, followed by randomization to oral dutasteride 0.5 mg once daily or placebo for 2 years. Patients eligible for inclusion were consenting men aged ≥ 50 years with moderate to severe symptoms (American Urological Symptom Index, AUA‐SI, score ≥ 12), a prostate volume of ≥ 30 mL, a serum prostate‐specific antigen (PSA) level of ≥ 1.5 or < 10 ng/mL, and a maximum urinary flow rate (Q max ) of ≤ 15 mL/s. BII scores were recorded at baseline and each study visit. Clinically and statistically significant changes in BII scores from baseline were investigated for each study visit. Logistical regression analysis was used to assess the significance of baseline prostate volume, symptoms, BII item 3, baseline Q max , serum dihydrotestosterone, testosterone, PSA, age and weight in predicting the BII score at 2 years. RESULTS: Dutasteride, but not placebo, resulted in clinically and statistically significant improvements in mean BII score from 6 months. Of patients with a baseline BII score of ≥ 5 (greatest symptomatic burden) treatment with dutasteride improved the scores by 2.41, while the scores in placebo‐treated patients only improved by 1.64. Dutasteride‐treated patients with a baseline BII score of < 5 (least symptom burden) had a clinically significant improvement in health status, while placebo‐treated patients deteriorated. Regression analysis showed that men with a combination of a baseline BII item‐3 score of 3 (bothered a lot) and a high symptom score (AUA‐SI ≥ 20) were more likely to be bothered by their symptoms at the end of the study. Men receiving placebo were also more likely to be bothered at the end of the study than were those receiving dutasteride. CONCLUSIONS: Dutasteride treatment is associated with clinically significant improvements in BII score, reflecting improvements in the quality of life of men with BPH. Taken together with previously reported improvements in prostate volume, lower urinary tract symptoms and urinary flow, and diminution of the risk of acute urinary retention and the need for BPH‐related surgery, dutasteride offers demonstrable efficacy in the management of BPH.Keywords
This publication has 23 references indexed in Scilit:
- Prostate Specific Antigen Predicts the Long-Term Risk of Prostate Enlargement: Results from the Baltimore Longitudinal Study of AgingJournal of Urology, 2002
- Long-Term Risk Of Re-Treatment Of Patients Using α-Blockers For Lower Urinary Tract SymptomsJournal of Urology, 2002
- PREVALENCE AND BOTHERSOMENESS OF LOWER URINARY TRACT SYMPTOMS IN BENIGN PROSTATIC HYPERPLASIA AND THEIR IMPACT ON WELL-BEINGJournal of Urology, 2001
- Prostate Volume and Serum Prostate–Specific Antigen as Predictors of Acute Urinary RetentionEuropean Urology, 2000
- Testing to Predict Outcome After Transurethral Resection of the ProstateJournal of Urology, 1997
- Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care studyClinical Therapeutics, 1997
- Natural History of Prostatism: Longitudinal Changes in Voiding Symptoms in Community Dwelling MenJournal of Urology, 1996
- Benign Prostatic Hyperplasia Specific Health Status Measures in Clinical Research: How Much Change in the American Urological Association Symptom Index and the Benign Prostatic Hyperplasia Impact Index is Perceptible to Patients?Journal of Urology, 1995
- A population-based study of health care-seeking behavior for treatment of urinary symptoms. The Olmsted County Study of Urinary Symptoms and Health Status Among MenArchives of Family Medicine, 1993
- Symptoms and signs of prostatism as risk factors for prostatectomyThe Prostate, 1990